Publications

2018

Al-Tamari HM, Dabral S, Schmall A, Sarvari P, Ruppert C, Paik J, et al. FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. EMBO Mol Med. 2018;10(2):276-293.
Iyengar NM, Chen I-, Zhou XK, Giri DD, Falcone DJ, Winston LA, et al. Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women. Cancer Prev Res (Phila). 2018;11(4):227-236.
Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, et al. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Sci Rep. 2018;8(1):7189.
Ooki A, Dinalankara W, Marchionni L, Tsay J-, Goparaju C, Maleki Z, et al. Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma. Oncogene. 2018;37(45):5967-5981.
Zadra G, Loda M. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. Cold Spring Harb Perspect Med. 2018;8(10).
Lin E, Scognamiglio T, Zhao Y, Schwartz TH, Phillips CD. Prognostic Implications of Gadolinium Enhancement of Skull Base Chordomas. AJNR Am J Neuroradiol. 2018;39(8):1509-1514.
Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, et al. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2018;124(5):1008-1015.
Tabbo F, Nottegar A, Guerrera F, Migliore E, Luchini C, Maletta F, et al. Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. Hum Pathol. 2018;75:167-178.
Gafeer MM, Mohammed KH, Ormenisan-Gherasim C, Choudhary F, Siddiqui MT, Cohen C. Diagnostic Utility of PD-L1 Expression in Lung Adenocarcinoma: Immunohistochemistry and RNA In Situ Hybridization. Appl Immunohistochem Mol Morphol. 2018;26(8):e86-e90.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700